The Role of Serum Anticholinergic Activity in ACVB Patients

Serum Anticholinergic Activity (SAA) and BIS-EEG as Potential Markers for Cognitive Ability and/or the Anticholinergic Medication in ACVB Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00782938

Enrollment

100

Registered

2008-10-31

Start date

2008-05-31

Completion date

2010-01-31

Last updated

2010-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acetylcholine, BIS-EEG, Cognition

Brief summary

Drugs with anticholinergic potential increase the risk of postoperative transient and persistent cognitive dysfunction especially in cardiac patients. The investigators main goal is to identify preoperative risk factors and to monitor postoperative patients' state in relation to SAA activity and bilateral BIS-EEG changes.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

55 Years to 90 Years

Healthy volunteers

Inclusion criteria

* written compliance to the study participation * a good knowledge in German speech * no red/ green blindness * no previous neurological and/or psychiatric illness * good ability to see and to hear * Mini-Mental-State-Examination (MMSE) better than 25 points

Exclusion criteria

* no written compliance to the study participation * bad knowledge in German speech * red/ green blindness * previous neurological and/or psychiatric illness * no ability to see and to hear * Mini-Mental-State-Examination (MMSE) lower than 25 points

Design outcomes

Primary

Measure	Time frame
Cognitive dysfunction measured by neurocognitive test battery	3 month postsurgery

Secondary

Measure	Time frame
SAA, BIS-EEG, descriptive patients' characteristics	24 h postsurgery

Countries

Germany

Outcome results